Development and Application of Next Generation Synthetic Biology Tools
Lead Research Organisation:
University of Manchester
Department Name: School of Medical Sciences
Abstract
A variety of micro-organisms including E. coli and S. cerevisiae (baker's yeast), are used in commercial bio-production processes to manufacture a number of products, ranging from high-value low-volume products, such bio-therapeutics (e.g. recombinant insulin), to mid-value products, (e.g. biocatalysts and specialised chemicals), to low-value bulk commodity products (e.g. succinic acid and biofuels). In addition, the same biotechnologies used in these production processes are commonly used in basic life science research. As such, the development of new gene control systems would be of great benefit in a number of applied and fundamental areas of biological and biomedical R&D. In particular, the research here seeks to develop novel protein production and metabolic engineering tools, and to demonstrate the applications of these novel synthetic biology tools in the context of the bioprocessing industry.
Within the pharmaceutical sector, biopharmaceuticals constitute 7 out of the 10 bestselling products. The global protein-based biopharmaceutical market had sales worth $70b in 2010, and this figure is set to increase to $110b by 2015. The reasons for the increase in projected global sales are thus: i) many of the targets of these therapeutic proteins are deemed 'undruggable' by traditional small molecule approaches, ii) therapeutic proteins often have superior safety and efficacy profiles, iii) the development times on average are shorter for therapeutic proteins than traditional therapies, iv) there is often limited or absent competition. However, although biopharmaceuticals offer many health benefits along with substantial commercial opportunities, their production remains a significant technical challenge.
Through this current study, I shall develop and demonstrate four important flavours of a novel gene co-expression technology, to allow multimeric protein products to be produced more effectively, along with the potential to provide a simpler and more efficient manufacturing process. Additionally, these co-expression technologies will be used to optimise a number of multivariate co-expression challenges, helping to guide metabolic engineering efforts. The outputs from this fellowship will lead to improved bioprocess efficiencies, with the potential to reduce both drug development times and manufacturing costs, and therefore the financial burden upon national healthcare providers. This research project will also generate technology and knowledge that will help maintain the UK's competitive edge, and will produce highly trained and skilled research personnel.
Within the pharmaceutical sector, biopharmaceuticals constitute 7 out of the 10 bestselling products. The global protein-based biopharmaceutical market had sales worth $70b in 2010, and this figure is set to increase to $110b by 2015. The reasons for the increase in projected global sales are thus: i) many of the targets of these therapeutic proteins are deemed 'undruggable' by traditional small molecule approaches, ii) therapeutic proteins often have superior safety and efficacy profiles, iii) the development times on average are shorter for therapeutic proteins than traditional therapies, iv) there is often limited or absent competition. However, although biopharmaceuticals offer many health benefits along with substantial commercial opportunities, their production remains a significant technical challenge.
Through this current study, I shall develop and demonstrate four important flavours of a novel gene co-expression technology, to allow multimeric protein products to be produced more effectively, along with the potential to provide a simpler and more efficient manufacturing process. Additionally, these co-expression technologies will be used to optimise a number of multivariate co-expression challenges, helping to guide metabolic engineering efforts. The outputs from this fellowship will lead to improved bioprocess efficiencies, with the potential to reduce both drug development times and manufacturing costs, and therefore the financial burden upon national healthcare providers. This research project will also generate technology and knowledge that will help maintain the UK's competitive edge, and will produce highly trained and skilled research personnel.
Technical Summary
This project will involve the development and application of a series of novel gene expression control biotechnologies in E. coli, to provide feedback control and multiple gene co-expression control for the controlled enhancement of the expression of multiple and/or difficult proteins. This work will include examples of practical application of these tools and systems for use in academia, the bioprocessing sector and other areas of the knowledge based bio-economy. Results from this study will also enable fundamental questions regarding bacterial physiology, stress response mechanisms and pathway flux engineering to be addressed, resulting in the establishment of a strong independent research career.
Firstly, a modular co-expression platform will be developed, which utilise the unique translational control of previously-developed orthogonal riboswitches, to regulate the expression of multiple viral RNA polymerases. This platform will be demonstrated by controlling the co-expression stoichiometry of the heavy and light chains of a Fab' antibody fragment. Secondly, a stress response sensing feedback system will be developed, utilizing a trans-acting antisense ncRNA input signal to permit recombinant gene expression to be matched to cellular synthetic capacity, enabling auto-regulatory optimisation of high-density fermentation cultures. Thirdly, multivariate pathway flux engineering will be used, in parallel with transcriptome profiling, to optimise glycosylation of proteins of bio-therapeutic importance within E. coli. Finally, a proof-of-principle study will seek to demonstrate the potential of using the bacterial c-di-GMP allosteric self-splicing ribozyme from C. difficile as a gene expression tool within a eukaryotic background. The systems developed here will be demonstrated with a number of practical examples of interest, and under fermentation conditions of relevance to the bioprocessing sector.
Firstly, a modular co-expression platform will be developed, which utilise the unique translational control of previously-developed orthogonal riboswitches, to regulate the expression of multiple viral RNA polymerases. This platform will be demonstrated by controlling the co-expression stoichiometry of the heavy and light chains of a Fab' antibody fragment. Secondly, a stress response sensing feedback system will be developed, utilizing a trans-acting antisense ncRNA input signal to permit recombinant gene expression to be matched to cellular synthetic capacity, enabling auto-regulatory optimisation of high-density fermentation cultures. Thirdly, multivariate pathway flux engineering will be used, in parallel with transcriptome profiling, to optimise glycosylation of proteins of bio-therapeutic importance within E. coli. Finally, a proof-of-principle study will seek to demonstrate the potential of using the bacterial c-di-GMP allosteric self-splicing ribozyme from C. difficile as a gene expression tool within a eukaryotic background. The systems developed here will be demonstrated with a number of practical examples of interest, and under fermentation conditions of relevance to the bioprocessing sector.
Planned Impact
WHO WILL BENEFIT: Pharmaceutical, biotech and contract manufacturing organisations charged with producing human therapeutic proteins on the hundred gram to kilogram scale could also use the co-expression systems developed here to produce biopharmaceuticals in E. coli. Interest from industry members has indicated how these technologies could find application in protein-based biopharmaceutical production processes. Drug discovery companies would benefit from novel co-expression technologies that permit the supply of toxic and/or insoluble drug targets e.g. Domainex. Additionally, many chemical companies that employ biocatalysts, such as Novozymes, DSM, Lonza, BASF and Dr. Reddy's, could also use these new co-expression tools for the production of multi-subunit enzymes. Similarly, oil companies such as Shell and BP have invested heavily in synthetic biology programmes to engineer microorganisms to produce new biofuels, where new co-expression tools would be equally important. Finally, there are many companies, such as Invitrogen, Qiagen, Promega, Stratagene, EMD Bioscience, Thermo Fisher, Bio-Rad, GE healthcare and Sigma-Aldrich, who sell commercial expression systems for use in bacteria. Any number of these companies could benefit through licensing agreements to use new systems based on the co-expression technologies developed in this project.
HOW WILL THEY BENEFIT: We will actively seek to communicate our findings to the wider community, through scientific meetings and scholarly publications (by continuing to publish in top journals such as: JACS, PNAS, Nat Biotechnol. & Nature Chem. Biol.). However, in order for the technology we develop to become widely adopted, particularly in industry, it will be important to first secure any intellectual property rights for all new inventions we discover. As the research progresses and our relationships with interested commercial partners develop, we will seek to commercially exploit these new technologies and license the IP for use in industrial-scale protein production processes. Improvements in bioprocess efficiency, generated from this fellowship, could lead to a potential reduction in both drug manufacturing costs and the financial burden upon national healthcare providers. This research project will also generate technology and knowledge that will help maintain the UK's competitive edge and will produce highly trained and skilled research personnel.
HOW WILL THEY BENEFIT: We will actively seek to communicate our findings to the wider community, through scientific meetings and scholarly publications (by continuing to publish in top journals such as: JACS, PNAS, Nat Biotechnol. & Nature Chem. Biol.). However, in order for the technology we develop to become widely adopted, particularly in industry, it will be important to first secure any intellectual property rights for all new inventions we discover. As the research progresses and our relationships with interested commercial partners develop, we will seek to commercially exploit these new technologies and license the IP for use in industrial-scale protein production processes. Improvements in bioprocess efficiency, generated from this fellowship, could lead to a potential reduction in both drug manufacturing costs and the financial burden upon national healthcare providers. This research project will also generate technology and knowledge that will help maintain the UK's competitive edge and will produce highly trained and skilled research personnel.
Organisations
- University of Manchester (Fellow, Lead Research Organisation)
- Centre for Process Innovation (CPI) (Collaboration)
- Cobra Biologics (Collaboration)
- University College London (Collaboration)
- Bioethanol Science and Technology Centre (CTBE) (Collaboration)
- Novo Nordisk (Collaboration)
- Biocatalysts Ltd (Collaboration)
- Chirotech Technology (Collaboration)
Publications
Kent R
(2019)
Systematic Evaluation of Genetic and Environmental Factors Affecting Performance of Translational Riboswitches.
in ACS synthetic biology
F. M. Machado L
(2019)
Directed evolution of the PcaV allosteric transcription factor to generate a biosensor for aromatic aldehydes
in Journal of Biological Engineering
Alvarez-Gonzalez G
(2019)
Genetically encoded biosensors for lignocellulose valorization.
in Biotechnology for biofuels
Tramontina R
(2020)
Consolidated production of coniferol and other high-value aromatic alcohols directly from lignocellulosic biomass
in Green Chemistry
Kent R
(2020)
Contemporary Tools for Regulating Gene Expression in Bacteria
in Trends in Biotechnology
Gupta R
(2020)
Suspended graphene arrays for gas sensing applications
in 2D Materials
Description | We have developed new engineered bacterial strains for the expression of recombinant proteins, this is important for the expression of high-value proteins such as enzymes and protein-based pharmaceuticals. The more efficient protein production afforded by these engineered strains, could for example find great promise to reduce the cost of producing protein-based therapeutics ultimately aiding access to therapy for patients and reducing the cost-burden on national healthcare provider such as the NHS. Secondly we have discovered a novel excretion pathway in bacterial cells. Protein translocation is an essential feature of cellular organisms. Bacteria, like all single-cell organisms, interact with their environment by translocation of proteins across their cell membranes via dedicated secretion pathways. Proteins destined for secretion are directed toward the secretion pathways by the presence of specific signal peptides. This study demonstrates that under conditions of both osmotic stress and translation stress, E. coli cells undergo an excretion phenomenon whereby signal peptide-less proteins are translocated across both the inner and outer cell membranes into the extracellular environment. Confirming the presence of alternative translocation/excretion pathways and understanding their function and regulation are thus important for fundamental microbiology and biotechnology. |
Exploitation Route | In the following research areas and industrial sectors: Applied Biotechnology, protein production, industrial biotechnology |
Sectors | Chemicals,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology |
URL | https://dixonlab.org |
Description | Has led to the adoption of new working practices within the industrial collaborators UK-based R&D facility, which has led to new business opportunities. The outcomes from this award have lead to further project entitle, Plasmid Copy Control - Enhanced pDNA Manufacture for Gene and Immunotherapy, in collaboration with a UKbased CMO, funded by a BBSRC IAA (BB/S506692/1) |
First Year Of Impact | 2014 |
Sector | Healthcare,Manufacturing, including Industrial Biotechology |
Impact Types | Economic |
Description | BBSRC IAA The University of Manchester |
Amount | £300,000 (GBP) |
Funding ID | BB/S506692/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2021 |
Description | BBSRC, DTP |
Amount | £80,000 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2015 |
End | 09/2020 |
Description | BBSRC-FAPESP joint call in advanced biofuels |
Amount | £2,082,439 (GBP) |
Funding ID | BB/P01738X/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2017 |
End | 02/2022 |
Description | BBSRC-FAPESP pump-priming award |
Amount | £35,000 (GBP) |
Funding ID | BB/L026244/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 08/2014 |
End | 07/2016 |
Description | BEPE |
Amount | £50,000 (GBP) |
Organisation | São Paulo Research Foundation (FAPESP) |
Sector | Public |
Country | Brazil |
Start | 01/2018 |
End | 12/2018 |
Description | BioCatNet Proof of Concept |
Amount | £35,032 (GBP) |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2015 |
End | 02/2016 |
Description | Cellulosomes - a versatile enzymatic scaffold platform for bioconversion of lignocellulosic biomass into value-added fine chemicals |
Amount | £50,000 (GBP) |
Organisation | São Paulo Research Foundation (FAPESP) |
Sector | Public |
Country | Brazil |
Start | 04/2019 |
End | 04/2020 |
Description | Commonwealth Scholarship Commission - Split Site PhD Placement |
Amount | £41,000 (GBP) |
Funding ID | INCN-2018-57 |
Organisation | UK Department for International Development |
Sector | Public |
Country | United Kingdom |
Start | 12/2018 |
End | 12/2019 |
Description | EPSRC CDT UCL |
Amount | £80,000 (GBP) |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2015 |
End | 08/2020 |
Description | Engineering Novel Allosteric Transcription Factor Recognition: Applications in Bio-catalysis and Synthetic Biology |
Amount | £80,000 (GBP) |
Funding ID | 2110033 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2018 |
End | 09/2022 |
Description | Enhanced Production and Process Analysis of Biotherapeutics - Antibody Fragments and Alternative Scaffolds |
Amount | £60,000 (GBP) |
Funding ID | 1621074 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2015 |
End | 09/2019 |
Description | IB Catalyst - Early Stage Feasibility |
Amount | £121,512 (GBP) |
Funding ID | BB/M011259/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 04/2015 |
End | 03/2016 |
Description | Indonesian Government Home funded PhD Srudenship |
Amount | £100,000 (GBP) |
Organisation | Government of Indonesia |
Sector | Public |
Country | Indonesia |
Start | 09/2016 |
End | 08/2020 |
Description | Plasmid Copy Control - Enhanced pDNA Manufacture for Gene and Immunotherapy |
Amount | £50,000 (GBP) |
Funding ID | n/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 02/2020 |
End | 07/2020 |
Description | Proof of Concept - CMBNet |
Amount | £35,032 (GBP) |
Funding ID | BIOCATNET PoC-012 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Department | Networks in Industrial Biotechnology and Bioenergy (NIBB) |
Sector | Academic/University |
Country | United Kingdom |
Start | 07/2015 |
End | 10/2015 |
Description | Responsive Mode |
Amount | £623,000 (GBP) |
Funding ID | BB/T005742/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 12/2020 |
End | 06/2024 |
Description | Rutherford Fund Strategic Partner Grants |
Amount | £149,500 (GBP) |
Funding ID | RF-2018-41 |
Organisation | Department for Business, Energy & Industrial Strategy |
Sector | Public |
Country | United Kingdom |
Start | 04/2018 |
End | 03/2019 |
Description | Science Without Boarders |
Amount | £120,000 (GBP) |
Organisation | National Council for Scientific and Technological Development (CNPq) |
Sector | Public |
Country | Brazil |
Start | 10/2015 |
End | 08/2020 |
Description | Synthetic Biology Centre Bid 2 |
Amount | £10,100,000 (GBP) |
Funding ID | BB/M017702/1 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start |
Description | Synthetic Biology: Development and Application Cellular Computation Devices |
Amount | £80,000 (GBP) |
Funding ID | 1618786 |
Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
Sector | Public |
Country | United Kingdom |
Start | 10/2015 |
End | 09/2019 |
Description | UK Catalysis Hub |
Amount | £172,000 (GBP) |
Funding ID | EP/M013219/1 |
Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2018 |
End | 04/2020 |
Description | Welcome Trust ISSF Research Consortia Award |
Amount | £44,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 10/2015 |
End | 09/2016 |
Title | Proteome analsyis of Translocation phenomenon |
Description | Proteome analsyis of Translocation phenomenon |
Type Of Material | Database/Collection of data |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | Manuscript published, Translation Stress Positively Regulates MscL-Dependent Excretion of Cytoplasmic Proteins MBio 2018, doi: 10.1128/mBio.02118-17. |
URL | http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD006474 |
Description | AS project |
Organisation | Biocatalysts Ltd |
Country | United Kingdom |
Sector | Private |
PI Contribution | The research project. |
Collaborator Contribution | Supply of materials to enable the research to proceed and desk analysis of commercial viability of the processes to be developed as part of the research. |
Impact | Too early |
Start Year | 2015 |
Description | AS project |
Organisation | Chirotech Technology |
Country | United Kingdom |
Sector | Private |
PI Contribution | The research project. |
Collaborator Contribution | Supply of materials to enable the research to proceed and desk analysis of commercial viability of the processes to be developed as part of the research. |
Impact | Too early |
Start Year | 2015 |
Description | Collaboration with CMO for biologics production |
Organisation | Cobra Biologics |
Country | United Kingdom |
Sector | Private |
PI Contribution | We have contributed IP, know-how, and research expertise to this collaboration |
Collaborator Contribution | The partners have contributed industry R&D and know-how |
Impact | Too earlier to say, the collaboration has led to successful joint grant funding. |
Start Year | 2013 |
Description | Collaboration with CTBE, Brazil |
Organisation | Bioethanol Science and Technology Centre (CTBE) |
Country | Brazil |
Sector | Private |
PI Contribution | During a Faculty-led Research Development visit to Brazil, we visited the Brazilian National Laboratory for Bioethanol (CTBE). Following this visit, myself and Fabio Squina (CTBE) have been in communication about applying ours interests in synthetic biology to facilitate enzyme discovery associated with lignin-biomass valorisation. We hosted visitors from the CTBE and other research institutes in Brazil at Industrial Biotechnology Bioenergy Meeting that I co-organised. This led to a successful funding application to the BBSRC/FAPESP (FAPPA) pump-priming call, to allow us to explore these preliminary ideas and facilitate further networking and research consortia building activities. Most recently we re-visited the CTBE to further develop collaborators links and build a research proposal. This has led to exchange of materials, a proposed exchange of personnel between my laboratory and the CTBE, and most recently to a large funding application to the BBSRC/FAPESP (>£2.5 UK). |
Collaborator Contribution | During a Faculty-led Research Development visit to Brazil, we visited the Brazilian National Laboratory for Bioethanol (CTBE). Following this visit, myself and Fabio Squina (CTBE) have been in communication about applying ours interests in synthetic biology to facilitate enzyme discovery associated with lignin-biomass valorisation. We hosted visitors from the CTBE and other research institutes in Brazil at Industrial Biotechnology Bioenergy Meeting that I co-organised. This led to a successful funding application to the BBSRC/FAPESP (FAPPA) pump-priming call, to allow us to explore these preliminary ideas and facilitate further networking and research consortia building activities. Most recently we re-visited the CTBE to further develop collaborators links and build a research proposal. This has led to exchange of materials, a proposed exchange of personnel between my laboratory and the CTBE, and most recently to a large funding application to the BBSRC/FAPESP (>£2.5 UK). |
Impact | Outcomes: A proposed funding application to the BBSRC/FAPESP (>£2.5 UK). Multi-discplianry collaboration: Synthetic Biology, Meta-transcriptomics, Enzyme discovery, biocatalysis, bioprocess development, life-cycle analysis. |
Start Year | 2013 |
Description | Collaboration with International biopharma company (2017- on going) |
Organisation | Novo Nordisk |
Country | Denmark |
Sector | Private |
PI Contribution | Following on from research data present and US conference, this international biopharma companies made contacted and expressed and expressed an interested in getting access to ort technology and establishing a collaboration |
Collaborator Contribution | We have discussed and applied a work program together over several months, and executed the appropriate legal agreements. The technical validation work is due to be initiated within Q1 2018 |
Impact | Outputs are still pending. |
Start Year | 2017 |
Description | Collaboration with UCL |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have developed whole cell biocatalysts for the biotransformation of waste/low value biomass residues into high-value fragrance and flavour compounds |
Collaborator Contribution | Scale up of the biotransformation process converting waste/low value biomass residues into high-value fragrance and flavour compounds |
Impact | Pending, outputs in preparation |
Start Year | 2016 |
Description | Collaboration with the c (CPI) |
Organisation | Centre for Process Innovation (CPI) |
Country | United Kingdom |
Sector | Private |
PI Contribution | The aim to better understand the process parameter associated with an unexpected excretion phenotype from bacterial cells. We provide stains and protocols. |
Collaborator Contribution | Access to facilities and advice on process validation and scale up. |
Impact | Too early |
Start Year | 2019 |
Description | BBSRC Enterprise Fellowships Networking Event |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | BBSRC Enterprise Fellowships Networking Event |
Year(s) Of Engagement Activity | 2017 |
Description | British Science Week Schools' Fair |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | Members of Dixon Lab participated in the British Science Week Schools' Fair (13-16th March 2018), 100 attendees |
Year(s) Of Engagement Activity | 2018 |
Description | Croda Open Innovation Day |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | New project ideas discussed. |
Year(s) Of Engagement Activity | 2017 |
Description | EuroScience Open Forum (ESOF) |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | EuroScience Open Forum (ESOF): +provide an open forum for debate on science and technology and research policies in Europe +strengthen the links between science and society +contribute to the creation of an integrated space for science and technology in Europe, linking research organisations and policies at national and EU levels; strive for a greater role of the EU in research and +influence science and technology policies. |
Year(s) Of Engagement Activity | 2016 |
URL | http://manchester2016.esof.eu/en/ |
Description | FLS Community Open Day |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Schools |
Results and Impact | An outreach stand about biotechnology for the production of fragrance compounds and public opinion of synthetic biology |
Year(s) Of Engagement Activity | 2016 |
Description | Institute Open Day (Outreach) |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | Prepare promotional material in advance of the meeting, and hosted the interactive stand 1,5 days tbc |
Year(s) Of Engagement Activity | 2014 |
Description | Institute Open Day (Outreach) |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | Synthetic Biology stand at MIB open-day attended by >200 A levels students |
Year(s) Of Engagement Activity | 2014,2015,2016 |
Description | Invited Speaker at Centre of Excellence in Biopharmaceuticals, UK 4th Annual Scientific Symposium |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Q&A Contact with new potential industrial collaborators |
Year(s) Of Engagement Activity | 2015 |
Description | Invited Speaker at European Congress on Biotechnology |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Q&A Lead to new contacts |
Year(s) Of Engagement Activity | 2014 |
Description | Invited Speaker at the UK-South Korea Synthetic Biology Workshop. Heathrow UK |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Q&A New potential collaborators in Korean |
Year(s) Of Engagement Activity | 2015 |
Description | Invited speaker at CTBE and UNICAMP |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Talks sparked Q&A, and supported subsequent discussions around research proposal Further funding applications |
Year(s) Of Engagement Activity | 2014 |
Description | Invited speaker at ELRIG Advances in Protein Technology |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | Regional |
Primary Audience | Professional Practitioners |
Results and Impact | Sparked Q&A immediately afterwards. Led to follow up discussions with three different researchers, two of which have led to ongoing collaborations We have transferred the technology discussed in the talk into a new collaborators institute, who is a leading national service provider in the relevant field. |
Year(s) Of Engagement Activity | 2013 |
URL | http://elrig.org/portfolio/advances-in-recombinant-protein-technology-2013/ |
Description | Invited speaker at Society of General Microbiology AGM, |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Participants in your research and patient groups |
Results and Impact | Q&A Follow up contact with members of the research community |
Year(s) Of Engagement Activity | 2014 |
Description | Rainbow Seed Fund Catapult Investor Insight Event, Court of Justice, London |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Industry/Business |
Results and Impact | Presentation on emerging areas from the academic research base to investors and press |
Year(s) Of Engagement Activity | 2017 |
Description | SEB Synthetic Biology Symposium |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Professional Practitioners |
Results and Impact | Talk sparked questions and discussions. A number of new potential collaboration contacts were made. Was asked to come for a Faculty visit at another institute |
Year(s) Of Engagement Activity | 2014 |
URL | http://www.sebiology.org/meetings/Past_Meetings/synthetic_biology/overview.html |
Description | SMART-Map Industrial Dialogue on Synthetic Biology |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Study participants or study members |
Results and Impact | Workshop on the responsible development of Synthetic Biology which forms part of the EU H2020 SMART-map project. |
Year(s) Of Engagement Activity | 2017 |
URL | http://projectsmartmap.eu/ |
Description | SynBioChem Workshop on Responsible Research and Innovation |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Study participants or study members |
Results and Impact | Roundtable discussant at SynBioChem Workshop on Responsible Research and Innovation |
Year(s) Of Engagement Activity | 2015 |
Description | iGEM Giant Jamboree |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Other audiences |
Results and Impact | Synthetic Biology iGEM Giant Jamboree |
Year(s) Of Engagement Activity | 2016 |
URL | http://2016.igem.org/Giant_Jamboree |